{"id":76627,"date":"2026-06-03T02:21:15","date_gmt":"2026-06-03T02:21:15","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/76627\/"},"modified":"2026-06-03T02:21:15","modified_gmt":"2026-06-03T02:21:15","slug":"novartis-cutting-more-jobs-at-east-hanover-hq-updated","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/76627\/","title":{"rendered":"Novartis cutting more jobs at East Hanover HQ (updated)"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/06\/play-icon.png\"\/> Listen to this article<\/p>\n<p>The basics:<\/p>\n<p><a href=\"https:\/\/njbiz.com\/tag\/novartis\/\" class=\"st_tag internal_tag \" rel=\"tag nofollow noopener\" title=\"Posts tagged with Novartis\" target=\"_blank\">Novartis<\/a> will eliminate 76 more positions at US HQ in <a href=\"https:\/\/njbiz.com\/tag\/east-hanover\/\" class=\"st_tag internal_tag \" rel=\"tag nofollow noopener\" title=\"Posts tagged with East Hanover\" target=\"_blank\">East Hanover<\/a><br \/>\nCuts tied to ongoing global <a href=\"https:\/\/njbiz.com\/tag\/restructuring\/\" class=\"st_tag internal_tag \" rel=\"tag nofollow noopener\" title=\"Posts tagged with restructuring\" target=\"_blank\">restructuring<\/a> plan<br \/>\nCompany investing billions in domestic manufacturing<br \/>\nDrugmaker pursuing acquisitions, new therapies<\/p>\n<p>Novartis is planning further cuts at its U.S. headquarters in New Jersey as part of an ongoing restructuring effort.\n<\/p>\n<p><a href=\"https:\/\/www.nj.gov\/labor\/assets\/PDFs\/WARN\/2026_WARN_Notice_Archive.pdf\" target=\"_blank\" rel=\"noopener nofollow\">In a filing with the state Department of Labor &amp; Workforce Development<\/a>, the Swiss pharmaceutical giant reported it will eliminate 76 positions at its East Hanover base in August.\n<\/p>\n<p>This marks the third time in 2026 that Novartis will slim down its New Jersey operations.<\/p>\n<p>In March, <a href=\"https:\/\/njbiz.com\/novartis-114-more-job-cuts-east-hanover-hq\/\" target=\"_blank\" rel=\"noopener nofollow\">the drugmaker said it planned 114 job cuts between June 26 and Nov. 27.<\/a> Last month, Novartis announced it would let go of 60 employees between July 24 and Nov. 20.\n<\/p>\n<p>A spokesperson for Novartis confirmed with NJBIZ <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/novartis-cuts-select-number-roles-biomedical-research-arm\" target=\"_blank\" rel=\"noopener nofollow\">previous reports<\/a> that the company is trimming positions within its <a href=\"https:\/\/njbiz.com\/tag\/biomedical-research\/\" class=\"st_tag internal_tag \" rel=\"tag nofollow noopener\" title=\"Posts tagged with biomedical research\" target=\"_blank\">biomedical research<\/a> arm. \u201cWhile this was a strategic decision, we recognize this is difficult news for those affected, and we remain committed to treating our colleagues with fairness, respect, and care,\u201d the spokesperson said.\n<\/p>\n<p>\u201cNovartis continually assesses opportunities to support our growth strategy as a focused innovative medicines company,\u201d the representative added. \u201cWe regularly evaluate our organizational setup to ensure it remains aligned with evolving priorities.\u201d<\/p>\n<p>Restructuring plan<\/p>\n<p>As of December 2025, Novartis\u2019 biomedical research department had about 5,720 full-time scientists, physicians and business professionals, <a href=\"https:\/\/www.novartis.com\/sites\/novartis_com\/files\/novartis-annual-report-2025.pdf\" target=\"_blank\" rel=\"noopener nofollow\">according to the company\u2019s annual report.<\/a>\n<\/p>\n<p>Those staffers are spread across Novartis sites in Switzerland, Massachusetts, New Jersey and California. The company has not yet disclosed if any <a href=\"https:\/\/njbiz.com\/tag\/layoffs\/\" class=\"st_tag internal_tag \" rel=\"tag nofollow noopener\" title=\"Posts tagged with layoffs\" target=\"_blank\">layoffs<\/a> will occur within its other U.S. biomedical research operations.\n<\/p>\n<p>Since unveiling its 2022 restructuring plan, <a href=\"https:\/\/njbiz.com\/novartis-east-hanover-layoffs-restructuring-2025\/\" target=\"_blank\" rel=\"noopener nofollow\">Novartis has cut more than 1,000 jobs in New Jersey<\/a> over multiple waves as it works to reshape its U.S. business.\u00a0The company has said it ultimately expects to phase out approximately 8,000 positions globally \u2013 or about 7% of its global workforce.<br \/>\n<img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-550437\" src=\"data:image\/svg+xml,%3Csvg%20xmlns=\" http:=\"\" alt=\"Novartis\" width=\"500\" height=\"306\" data-lazy- data-lazy- data-lazy-src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/06\/Novartis_medicines_Depositphotos_722626450_XL.jpg\"\/><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-550437\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/06\/Novartis_medicines_Depositphotos_722626450_XL.jpg\" alt=\"Novartis\" width=\"500\" height=\"306\"  \/>Novartis recently reported progress on its April 2025 commitment to invest $23 billion over the next five years to boost U.S.-based manufacturing, research and development. \u2013 DEPOSIT PHOTOS\n<\/p>\n<p>Novartis also recently said it will cut about 220 jobs in Germany as part of a planned closure of an 83-year-old production site by the end of 2028, <a href=\"https:\/\/www.reuters.com\/business\/world-at-work\/novartis-cut-220-jobs-it-closes-german-site-2026-05-05\/\" target=\"_blank\" rel=\"noopener nofollow\">Reuters reported<\/a>. According to the news outlet, the plant makes older drugs in its portfolio that come in traditional solid oral dosage forms like tablets and capsules.\n<\/p>\n<p>The company also said it is investing about $40 billion to build a new facility in eastern Germany that will specialize in radioligand therapies. The site is expected to begin operations in 2027.\n<\/p>\n<p>Building up<\/p>\n<p>At the same time, Novartis is also focusing on manufacturing, innovation and new therapies.\n<\/p>\n<p><a href=\"https:\/\/njbiz.com\/novartis-23b-us-manufacturing-expansion\/\" target=\"_blank\" rel=\"noopener nofollow\">The company recently reported progress on its April 2025 commitment to invest $23 billion<\/a> over the next five years to <a href=\"https:\/\/njbiz.com\/novartis-investing-23b-on-us-manufacturing-rd-build-up\/\" target=\"_blank\" rel=\"noopener nofollow\">boost U.S.-based manufacturing, research and development.<\/a>\n<\/p>\n<p>According to the company, development is underway on several new facilities that will support its goal of producing 100% of key medicines domestically. Novartis expects to create more than 1,000 new positions for skilled workers, such as scientists and engineers, along with an additional 4,000 jobs for support staff and construction overall.\n<\/p>\n<p>Other job cuts affecting:<\/p>\n<p>The investment comes as Novartis prepares for patent expirations of heart medicine Entresto and plaque psoriasis biologic Cosentyx. Earlier this year, <a href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/novartis-expects-low-single-digit-decline-2026-operating-profit-2026-02-04\/\" target=\"_blank\" rel=\"noopener nofollow\">the company warned that profits would decline as some of its best-selling drugs lose their protections.\u00a0<\/a>In a bid to offset the losses, Novartis is planning a series of acquisitions.\n<\/p>\n<p>In March, the company revealed it shell out up to $2 billion to acquire <a href=\"https:\/\/njbiz.com\/novartis-buy-excellergy-2b-allergy-drugs\/\" target=\"_blank\" rel=\"noopener nofollow\">California-based biotech Excellergy.<\/a> As part of the deal, Novartis will add an early-stage drug candidate to its existing allergy portfolio. That news came days after Novartis announced plans to acquire <a href=\"https:\/\/njbiz.com\/novartis-acquires-synnovation-breast-cancer-drug\/\" target=\"_blank\" rel=\"noopener nofollow\">Synnovation subsidiary Pikavation Therapeutics<\/a>. It will pay up to $3 billion for that deal to secure the rights to an experimental breast cancer drug.\n<\/p>\n<p>Editor\u2019s note: This story was updated at 2:32 p.m. May 26, 2026, to include a statement from Novartis.<\/p>\n","protected":false},"excerpt":{"rendered":"Listen to this article The basics: Novartis will eliminate 76 more positions at US HQ in East Hanover&hellip;\n","protected":false},"author":2,"featured_media":76628,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[3819,40005,4175,36055,2984,206,4587,2986],"class_list":["post-76627","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-biomedical-research","tag-biotech-jobs","tag-drug-manufacturing","tag-east-hanover","tag-layoffs","tag-novartis","tag-pharmaceutical-industry","tag-restructuring"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116683793005911173","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/76627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=76627"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/76627\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/76628"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=76627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=76627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=76627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}